Alternating, intravenous administration of two replicating arenaviral vectors induce tumor-specific responses exceeding 50% of the circulating CD8 T cells 2-vector approach resulted in tumor cures and ...
James Miskin brings 25 years of cell and gene therapy experience to an advisory role focused on further unlocking ViroCell’s potential LONDON & NEW YORK--(BUSINESS WIRE)--ViroCell Biologics (“ViroCell ...
- HB-202/HB-201 alternating two-vector therapy is added as an additional arm that expands the ongoing HB-201 clinical trial - Pre-clinical data show that adding an additional arenaviral vector to ...
After an investigation in an adverse event, Bluebird Bio announced that it is “very unlikely” that the BB305 lentiviral vector (LVV) caused the case of acute myeloid leukemia (AML) which was reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results